About vincristine
Vinca alkaloid chemotherapy medicine
Used for
- Treats acute leukaemia and other blood cancers.
- Treats some lymphomas and solid tumours, usually in combination therapy.
Usual adult dose
Varies by cancer and regimen; commonly 1.4 mg/m² intravenously once weekly, with a maximum of 2 mg per dose.
Usual dose in children
Varies by cancer and regimen; commonly 1.5–2 mg/m² intravenously weekly, with a maximum of 2 mg per dose.
Common side effects
- Constipation and abdominal pain
- Numbness, tingling, or weakness from nerve damage
- Hair loss
- Low blood-cell counts, increasing infection or bleeding risk
Important warnings
- For intravenous use only; injection into the spinal fluid can be fatal.
- Must be given by experienced cancer-care staff.
- Nerve damage and severe constipation can occur.
- Dose may need adjustment with liver problems or interacting medicines.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment; discuss reliable contraception with the cancer-care team.
Breastfeeding
Breastfeeding is not recommended during treatment because of potential harm to the infant.
Interactions
- Strong CYP3A inhibitors, such as itraconazole, may increase toxicity.
- Strong CYP3A inducers, such as rifampicin, may reduce effectiveness.
- Other medicines that harm nerves or suppress blood cells may increase side effects.
- Live vaccines may cause serious infection during chemotherapy.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.